Guiera Senegalensis (Guiera senegalensis): Benefits, Dosage, Safety & Evidence

Questions fréquentes

How does Guiera senegalensis work against malaria and parasites?

Guiera senegalensis contains bioactive compounds including ellagitannins, flavonoids, alkaloids, and saponins that exhibit antiparasitic and antimicrobial properties. These compounds are believed to interfere with parasite metabolism and disrupt cell membrane integrity, though the precise mechanism requires further research. Preliminary studies and extensive traditional use support its effectiveness against Plasmodium species and intestinal parasites. Evidence level: C (preliminary clinical evidence).

Is Guiera senegalensis safe during pregnancy and breastfeeding?

No, Guiera senegalensis is contraindicated during pregnancy and breastfeeding. The plant contains alkaloids and other bioactive compounds that may stimulate uterine contractions or cause harm to fetal development. Traditional knowledge and available evidence classify it as unsafe for pregnant women. Women who are breastfeeding should also avoid this herb due to insufficient safety data and potential transfer to infant through milk. Evidence level: C.

What is the recommended dosage for Guiera senegalensis?

The traditional adult dosage for Guiera senegalensis is a decoction prepared from bark or leaves, taken as 200 mL three times daily. This preparation is commonly used for malaria, intestinal parasites, and respiratory infections. Standardized commercial extracts are not widely available, so dosing relies on traditional preparation methods. Duration of treatment should be limited and supervised by a qualified healthcare practitioner. Evidence level: C (traditional use).

Does Guiera senegalensis interact with any medications?

Limited clinical data exists on specific drug interactions for Guiera senegalensis. Due to its high tannin content, it may potentially reduce the absorption of certain medications and minerals when taken concurrently. Patients taking antimalarial drugs, anticoagulants, or medications metabolized by the liver should consult a healthcare provider before use. The herb's effects on cytochrome P450 enzymes have not been well characterized. Evidence level: C.

What are the side effects of Guiera senegalensis?

Common side effects of Guiera senegalensis include nausea and digestive upset, particularly when taken in large doses or on an empty stomach. The significant tannin content may cause gastrointestinal irritation in sensitive individuals. Excessive or prolonged use is not recommended and may worsen digestive symptoms. This herb is contraindicated in children under 6 years of age. Discontinue use if adverse reactions occur. Evidence level: C (traditional use reports).

Fiche d'information compilée à partir de PubMed

Cette fiche a été compilée à partir de résumés PubMed (NIH) avec l'assistance d'une IA. Chaque affirmation factuelle est citée par un article PubMed réel (voir la liste des sources). Elle n'a pas encore été révisée par un humain — confirmez auprès d'un professionnel de santé avant utilisation.

Compilé à partir de 30 articles PubMed · modèle : gemma4:31b

Résumé

Guiera senegalensis is a small shrub from the Sudano-Sahelian zone used in African traditional medicine for various infectious and metabolic disorders [PMID:33011373, PMID:28283004].

Contexte

Guiera senegalensis J.F. Gmel. (Combretaceae), also known as "Gubeish" in Sudan, is a small shrub abundant in semi-desert areas of the Sudano-Sahelian zone [PMID:33011373]. It is considered one of the most important medicinal plants in West Africa [PMID:18793484].

Usages traditionnels

It is widely used in African traditional medicine as a tonic and for treating respiratory and gastrointestinal disorders, microbial and parasitic infections [PMID:33011373], diabetes [PMID:33299821], epilepsy, and depression [PMID:35567150]. In Nigeria, it is used for the treatment of diarrhea and ulcers [PMID:15740894].

Composés actifs

Identified compounds include beta-carboline alkaloids (harman, tetrahydroharman, and harmalan), guieranone A (a naphthyl butenone) [PMID:16443341], flavonoids (quercetin, myricetin-3-O-rhamnoside, rutin, naringenin) [PMID:32435135, PMID:28283004], gallic acid [PMID:28283004], and biomarkers such as beta-amyrin, beta-sitosterol, lupeol, and ursolic acid [PMID:29991912].

Mécanisme d'action

In the context of fowlpoxvirus inhibition, a gall extract is suggested to activate the alternative complement pathway and inhibit FPV-induced cholester [PMID:16191693]. Leaf extracts have demonstrated the ability to ameliorate acetylcholinesterase (AChE) activity and oxidative stress in zebrafish models [PMID:35567150].

Preuves cliniques

Preuve DDiabetes

Root extracts showed glucose-lowering potential in a diabetic rat model [PMID:33299821]

Preuve DGastric Ulcers

Aqueous root extracts showed ulcer-protective effects in rodents [PMID:15740894]; aqueous leaf extracts significantly decreased the ulcer index in ethanol, water immersion, and Aspirin induced models in rats [PMID:23870464]

Preuve DDiarrhea

Aqueous root extract demonstrated anti-diarrhoeal properties by significantly reducing intestinal transit in mice [PMID:15740894]

Preuve DHepatitis B Virus (HBV)

Leaf extracts and isolated flavonoids (quercetin and myricetin-3-O-rhamnoside) inhibited the synthesis of HBsAg and HBeAg in vitro [PMID:29991912, PMID:32435135]

Preuve DMalaria

Extracts showed transmission blocking activity against the early vector stages of Plasmodium falciparum in Anopheles coluzzii mosquitoes [PMID:24735564]; total alkaloid extracts and beta-carboline alkaloids showed antiplasmodial activity in vitro [PMID:16443341]

Preuve D

Sécurité et effets indésirables

A toxicological study in Wistar rats using an aqueous extract (2 g/kg daily for six months) did not report adverse lesions in examined organs (heart, lungs, kidneys, brain, cerebellum, spleen, and liver) [PMID:14679980]. However, guieranone A showed high cytotoxicity toward human monocytes [PMID:16443341].

Synthèse des preuves

The evidence consists primarily of in vitro studies and animal models (rats, mice, zebrafish, and chicken eggs), indicating promising pharmacological activities, but there are no human clinical trials provided.

Sources PubMed

1.PMID: 33011373 (2021) — Ethnopharmacological uses, phytochemistry and pharmacological activities of Guiera senegalensis J.F. Gmel. (Combretaceae). · Journal of ethnopharmacology
2.PMID: 18793484 (2008) — Botanical characterization of Guiera senegalensis leaves. · Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada
3.PMID: 33299821 (2020) — Glucose-lowering potential of Guiera senegalensis roots in a diabetic rat model. · Avicenna journal of phytomedicine
4.PMID: 15740894 (2005) — Anti-diarrhoeal and ulcer-protective effects of the aqueous root extract of Guiera senegalensis in rodents. · Journal of ethnopharmacology
5.PMID: 16443341 (2006) — Phytochemical and pharmacological study of roots and leaves of Guiera senegalensis J.F. Gmel (Combretaceae).

Guiera Senegalensis

Sources et citations

Calculer une dose sûre de Guiera Senegalensis